Details of the Drug

General Information of Drug (ID: DM1V329)

Drug Name
Conivaptan
Synonyms
Conivaptan [INN]; YM 087; YM087; Conivaptan (INN); Vaprisol (TN); YM-087; N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide; N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}biphenyl-2-carboxamide; 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide
Indication
Disease Entry ICD 11 Status REF
Euvolemic hyponatremia 5C72 Approved [1], [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 498.6
Topological Polar Surface Area (xlogp) 5.7
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 3 mL/min/kg [4]
Elimination
1% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.1461 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.01% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.76 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.15 mg/mL [3]
Chemical Identifiers
Formula
C32H26N4O2
IUPAC Name
N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide
Canonical SMILES
CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6
InChI
InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)
InChIKey
IKENVDNFQMCRTR-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
151171
ChEBI ID
CHEBI:681850
CAS Number
210101-16-9
DrugBank ID
DB00872
TTD ID
D0VU2X
INTEDE ID
DR0376

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vasopressin V1a receptor (V1AR) TT4TFGN V1AR_HUMAN Modulator [6], [7]
Vasopressin V2 receptor (V2R) TTK8R02 V2R_HUMAN Modulator [6], [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Euvolemic hyponatremia
ICD Disease Classification 5C72
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vasopressin V1a receptor (V1AR) DTT AVPR1A 8.89E-04 -0.12 -0.34
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 5.10E-04 6.44E-02 2.85E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Conivaptan
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Tolvaptan DMIWFRL Major Decreased metabolism of Conivaptan caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [35]
Coadministration of a Drug Treating the Disease Different from Conivaptan (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Clindamycin DM15HL8 Moderate Decreased metabolism of Conivaptan caused by Clindamycin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [36]
Repaglinide DM5SXUV Moderate Decreased metabolism of Conivaptan caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [37]
Ivosidenib DM8S6T7 Major Decreased metabolism of Conivaptan caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [38]
Midostaurin DMI6E0R Major Decreased metabolism of Conivaptan caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [39]
Idarubicin DMM0XGL Moderate Decreased clearance of Conivaptan due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [40]
Oliceridine DM6MDCF Major Decreased metabolism of Conivaptan caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [41]
Ivabradine DM0L594 Major Decreased metabolism of Conivaptan caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [42]
Bepridil DM0RKS4 Major Decreased metabolism of Conivaptan caused by Bepridil mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [35]
Dronedarone DMA8FS5 Major Decreased metabolism of Conivaptan caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [42]
Nifedipine DMSVOZT Moderate Decreased metabolism of Conivaptan caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [35]
Bedaquiline DM3906J Moderate Decreased metabolism of Conivaptan caused by Bedaquiline mediated inhibition of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [43]
Cilostazol DMZMSCT Major Decreased metabolism of Conivaptan caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [44]
Posaconazole DMUL5EW Major Decreased metabolism of Conivaptan caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [42]
Budesonide DMJIBAW Major Decreased metabolism of Conivaptan caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [45]
Tindamax DM3OWT4 Moderate Decreased metabolism of Conivaptan caused by Tindamax mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Rabeprazole DMMZXIW Moderate Decreased metabolism of Conivaptan caused by Rabeprazole mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Troleandomycin DMUZNIG Major Decreased metabolism of Conivaptan caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [42]
Telithromycin DMZ4P3A Major Decreased metabolism of Conivaptan caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [42]
Cariprazine DMJYDVK Major Decreased metabolism of Conivaptan caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [46]
Erdafitinib DMI782S Major Decreased metabolism of Conivaptan caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [47]
Pexidartinib DMS2J0Z Moderate Decreased metabolism of Conivaptan caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [35]
Talazoparib DM1KS78 Moderate Decreased clearance of Conivaptan due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [48]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Conivaptan caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [49]
Lapatinib DM3BH1Y Major Decreased metabolism of Conivaptan caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [42]
HKI-272 DM6QOVN Major Decreased metabolism of Conivaptan caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [50]
LY2835219 DM93VBZ Major Decreased metabolism of Conivaptan caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [51]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Conivaptan caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Tucatinib DMBESUA Major Decreased metabolism of Conivaptan caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [42]
Palbociclib DMD7L94 Major Decreased metabolism of Conivaptan caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [52]
Letrozole DMH07Y3 Moderate Decreased metabolism of Conivaptan caused by Letrozole mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Conivaptan caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Conivaptan caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [42]
Bosutinib DMTI8YE Major Decreased metabolism of Conivaptan caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [42]
Trastuzumab Emtansine DMU1LXS Moderate Decreased metabolism of Conivaptan caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [53]
Atorvastatin DMF28YC Major Decreased metabolism of Conivaptan caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [54]
Macitentan DMP79A1 Major Decreased metabolism of Conivaptan caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [55]
PF-04449913 DMSB068 Major Decreased metabolism of Conivaptan caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [56]
Salmeterol DMIEU69 Major Decreased metabolism of Conivaptan caused by Salmeterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [42]
Indacaterol DMQJHR7 Minor Decreased clearance of Conivaptan due to the transporter inhibition by Indacaterol. Chronic obstructive pulmonary disease [CA22] [57]
Dihydrocodeine DMB0FWL Moderate Decreased metabolism of Conivaptan caused by Dihydrocodeine mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [53]
Levomilnacipran DMV26S8 Major Decreased metabolism of Conivaptan caused by Levomilnacipran mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [58]
Regorafenib DMHSY1I Moderate Decreased metabolism of Conivaptan caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [42]
Intedanib DMSTA36 Moderate Decreased clearance of Conivaptan due to the transporter inhibition by Intedanib. Colorectal cancer [2B91] [59]
Drospirenone DM1A9W3 Major Decreased metabolism of Conivaptan caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [42]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Conivaptan caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [35]
Ulipristal DMBNI20 Minor Decreased metabolism of Conivaptan caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [44]
Mestranol DMG3F94 Moderate Decreased metabolism of Conivaptan caused by Mestranol mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [53]
Halothane DM80OZ5 Moderate Decreased metabolism of Conivaptan caused by Halothane mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [35]
Cocaine DMSOX7I Moderate Decreased metabolism of Conivaptan caused by Cocaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [53]
Osilodrostat DMIJC9X Major Decreased metabolism of Conivaptan caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [44]
Ivacaftor DMZC1HS Major Decreased metabolism of Conivaptan caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [35]
Vilazodone DM4LECQ Major Decreased metabolism of Conivaptan caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [60]
Escitalopram DMFK9HG Minor Decreased metabolism of Conivaptan caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [61]
OPC-34712 DMHG57U Major Decreased metabolism of Conivaptan caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [62]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Conivaptan caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [63]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Conivaptan caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [53]
Oxybutynine DMJPBAX Moderate Decreased metabolism of Conivaptan caused by Oxybutynine mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [35]
Ospemifene DMC4GEI Moderate Decreased metabolism of Conivaptan caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [64]
Ingrezza DMVPLNC Major Additive CNS depression effects by the combination of Conivaptan and Ingrezza. Dystonic disorder [8A02] [65]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Conivaptan caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Tiagabine DMKSQG0 Moderate Decreased metabolism of Conivaptan caused by Tiagabine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Stiripentol DMMSDOY Moderate Decreased metabolism of Conivaptan caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Clonazepam DMTO13J Moderate Decreased metabolism of Conivaptan caused by Clonazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Lacosamide DMVM6QR Moderate Decreased metabolism of Conivaptan caused by Lacosamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [42]
Cannabidiol DM0659E Minor Decreased metabolism of Conivaptan caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [44]
Bay 80-6946 DMLOS5R Major Decreased clearance of Conivaptan due to the transporter inhibition by Bay 80-6946. Follicular lymphoma [2A80] [66]
Tazemetostat DMWP1BH Major Decreased metabolism of Conivaptan caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [67]
Solifenacin DMG592Q Major Decreased metabolism of Conivaptan caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [42]
Mirabegron DMS1GYT Minor Decreased metabolism of Conivaptan caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [68]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Conivaptan caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [69]
Itraconazole DMCR1MV Major Decreased metabolism of Conivaptan caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [42]
Miconazole DMPMYE8 Moderate Decreased metabolism of Conivaptan caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [70]
Ketoconazole DMPZI3Q Major Decreased metabolism of Conivaptan caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [42]
Ripretinib DM958QB Major Decreased metabolism of Conivaptan caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [42]
Sunitinib DMCBJSR Moderate Decreased metabolism of Conivaptan caused by Sunitinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [42]
Avapritinib DMK2GZX Major Decreased metabolism of Conivaptan caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [44]
Colchicine DM2POTE Major Decreased metabolism of Conivaptan caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [71]
Boceprevir DMBSHMF Major Decreased metabolism of Conivaptan caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [42]
Simeprevir DMLUA9D Major Decreased metabolism of Conivaptan caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [42]
Telaprevir DMMRV29 Major Decreased metabolism of Conivaptan caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [42]
Daclatasvir DMSFK9V Major Decreased metabolism of Conivaptan caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [44]
Rifapentine DMCHV4I Moderate Increased metabolism of Conivaptan caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [72]
MK-1439 DM215WE Minor Decreased metabolism of Conivaptan caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [73]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Conivaptan caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [42]
Tipranavir DM8HJX6 Moderate Decreased metabolism of Conivaptan caused by Tipranavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Dolutegravir DMCZGRE Minor Decreased metabolism of Conivaptan caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [74]
Saquinavir DMG814N Major Decreased metabolism of Conivaptan caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [42]
Etravirine DMGV8QU Moderate Decreased metabolism of Conivaptan caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [75]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Conivaptan caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [42]
Atazanavir DMSYRBX Major Decreased metabolism of Conivaptan caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [42]
Maraviroc DMTL94F Major Decreased metabolism of Conivaptan caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [76]
BMS-201038 DMQTAGO Major Decreased metabolism of Conivaptan caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [42]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Conivaptan caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [77]
Aliskiren DM1BV7W Moderate Decreased metabolism of Conivaptan caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [78]
Levamlodipine DM92S6N Moderate Decreased metabolism of Conivaptan caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [35]
Retapamulin DM9JXB7 Minor Decreased metabolism of Conivaptan caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [79]
TP-434 DM5A31S Minor Decreased metabolism of Conivaptan caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [80]
Berotralstat DMWA2DZ Major Decreased clearance of Conivaptan due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [81]
Suvorexant DM0E6S3 Major Decreased metabolism of Conivaptan caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [42]
Ramelteon DM7IW9J Moderate Decreased metabolism of Conivaptan caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [82]
Triazolam DMETYK5 Major Decreased metabolism of Conivaptan caused by Triazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [35]
Zaleplon DMGFWSM Moderate Decreased metabolism of Conivaptan caused by Zaleplon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [35]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Conivaptan caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [83]
ITI-007 DMUQ1DO Major Decreased metabolism of Conivaptan caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [84]
Estazolam DMZGXUM Moderate Decreased metabolism of Conivaptan caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [35]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Conivaptan caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [85]
Naloxegol DML0B41 Major Decreased metabolism of Conivaptan caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [42]
Pemigatinib DM819JF Major Decreased metabolism of Conivaptan caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [44]
Crizotinib DM4F29C Major Decreased metabolism of Conivaptan caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [42]
Brigatinib DM7W94S Major Decreased metabolism of Conivaptan caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [86]
Ceritinib DMB920Z Major Decreased metabolism of Conivaptan caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [42]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Conivaptan caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [87]
PF-06463922 DMKM7EW Major Decreased metabolism of Conivaptan caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [88]
Osimertinib DMRJLAT Major Decreased metabolism of Conivaptan caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [89]
Pralsetinib DMWU0I2 Major Decreased metabolism of Conivaptan caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [90]
Capmatinib DMYCXKL Major Decreased metabolism of Conivaptan caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [91]
Selpercatinib DMZR15V Major Decreased metabolism of Conivaptan caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [44]
Artemether DM48QOT Major Decreased metabolism of Conivaptan caused by Artemether mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [42]
Halofantrine DMOMK1V Major Decreased metabolism of Conivaptan caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [92]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Conivaptan caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [42]
Idelalisib DM602WT Major Decreased metabolism of Conivaptan caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [42]
IPI-145 DMWA24P Major Decreased metabolism of Conivaptan caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [93]
Acalabrutinib DM7GCVW Major Decreased metabolism of Conivaptan caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [94]
Ibrutinib DMHZCPO Major Decreased metabolism of Conivaptan caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [42]
Ponatinib DMYGJQO Major Decreased metabolism of Conivaptan caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [42]
Arry-162 DM1P6FR Moderate Decreased clearance of Conivaptan due to the transporter inhibition by Arry-162. Melanoma [2C30] [42]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Conivaptan caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [95]
Dienestrol DMBSXI0 Moderate Decreased metabolism of Conivaptan caused by Dienestrol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [53]
Ethinyl estradiol DMODJ40 Moderate Decreased metabolism of Conivaptan caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [53]
Ubrogepant DM749I3 Moderate Decreased metabolism of Conivaptan caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [96]
Almogran DM7I64Z Moderate Decreased metabolism of Conivaptan caused by Almogran mediated inhibition of CYP450 enzyme. Migraine [8A80] [35]
Rimegepant DMHOAUG Moderate Decreased metabolism of Conivaptan caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [97]
Exjade DMHPRWG Moderate Decreased metabolism of Conivaptan caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [98]
Flibanserin DM70DTN Major Decreased metabolism of Conivaptan caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [99]
Panobinostat DM58WKG Major Decreased metabolism of Conivaptan caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [100]
Siponimod DM2R86O Major Decreased metabolism of Conivaptan caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [42]
Romidepsin DMT5GNL Moderate Decreased metabolism of Conivaptan caused by Romidepsin mediated inhibition of CYP450 enzyme. Mycosis fungoides [2B01] [101]
Fedratinib DM4ZBK6 Major Decreased metabolism of Conivaptan caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [44]
Ruxolitinib DM7Q98D Major Decreased metabolism of Conivaptan caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [102]
Dasatinib DMJV2EK Major Decreased metabolism of Conivaptan caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [42]
Busulfan DMXYJ9C Moderate Decreased metabolism of Conivaptan caused by Busulfan mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [35]
Netupitant DMEKAYI Minor Decreased metabolism of Conivaptan caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [103]
Granisetron DMIUW25 Moderate Decreased metabolism of Conivaptan caused by Granisetron mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [35]
Ondansetron DMOTQ1I Moderate Decreased metabolism of Conivaptan caused by Ondansetron mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [35]
Entrectinib DMMPTLH Major Decreased metabolism of Conivaptan caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [42]
Sibutramine DMFJTDI Moderate Decreased metabolism of Conivaptan caused by Sibutramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [35]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Conivaptan caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [104]
S-297995 DM26IH8 Moderate Decreased metabolism of Conivaptan caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [44]
Olaparib DM8QB1D Major Decreased metabolism of Conivaptan caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [42]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Conivaptan caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [105]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Conivaptan caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [106]
Hydrocodone DMQ2JO5 Major Decreased metabolism of Conivaptan caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [107]
Istradefylline DM20VSK Major Decreased metabolism of Conivaptan caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [108]
Pimavanserin DMR7IVC Major Decreased metabolism of Conivaptan caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [109]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Conivaptan caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [35]
Abametapir DM2RX0I Moderate Decreased metabolism of Conivaptan caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [110]
Lefamulin DME6G97 Major Decreased clearance of Conivaptan due to the transporter inhibition by Lefamulin. Pneumonia [CA40] [111]
Ergonovine DM0VEC1 Major Decreased metabolism of Conivaptan caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [112]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Conivaptan caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [113]
ABIRATERONE DM8V75C Minor Decreased metabolism of Conivaptan caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [114]
Enzalutamide DMGL19D Moderate Decreased metabolism of Conivaptan caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [115]
Darolutamide DMV7YFT Moderate Decreased clearance of Conivaptan due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [116]
Silodosin DMJSBT6 Major Decreased metabolism of Conivaptan caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [42]
Riociguat DMXBLMP Moderate Decreased metabolism of Conivaptan caused by Riociguat mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [42]
Everolimus DM8X2EH Major Decreased metabolism of Conivaptan caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [42]
Axitinib DMGVH6N Major Decreased metabolism of Conivaptan caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [42]
Temsirolimus DMS104F Major Increased metabolism of Conivaptan caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [42]
Ciclesonide DM2NA4K Moderate Decreased metabolism of Conivaptan caused by Ciclesonide mediated inhibition of CYP450 enzyme. Respiratory system disease [CB40-CB7Z] [117]
Upadacitinib DM32B5U Major Decreased metabolism of Conivaptan caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [118]
Tofacitinib DMBS370 Major Decreased metabolism of Conivaptan caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [42]
Dexamethasone DMMWZET Moderate Decreased metabolism of Conivaptan caused by Dexamethasone mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [117]
Quetiapine DM1N62C Major Decreased metabolism of Conivaptan caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [119]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Conivaptan caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [35]
Iloperidone DM6AUFY Major Decreased metabolism of Conivaptan caused by Iloperidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [120]
Avanafil DM75CXN Major Decreased metabolism of Conivaptan caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [42]
Voxelotor DMCS6M5 Major Decreased metabolism of Conivaptan caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [121]
LDE225 DMM9F25 Major Decreased metabolism of Conivaptan caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [122]
Larotrectinib DM26CQR Major Decreased metabolism of Conivaptan caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [42]
Methylprednisolone DM4BDON Major Decreased metabolism of Conivaptan caused by Methylprednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [117]
Docetaxel DMDI269 Major Decreased metabolism of Conivaptan caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [123]
Trabectedin DMG3Y89 Major Decreased metabolism of Conivaptan caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [42]
Armodafinil DMGB035 Minor Decreased metabolism of Conivaptan caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [42]
LEE011 DMMX75K Major Decreased metabolism of Conivaptan caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [44]
Taxol DMUOT9V Moderate Decreased metabolism of Conivaptan caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [35]
Doxorubicin DMVP5YE Moderate Decreased metabolism of Conivaptan caused by Doxorubicin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [35]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Conivaptan caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [42]
Fostamatinib DM6AUHV Major Decreased metabolism of Conivaptan caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [124]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Conivaptan due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [105]
Apixaban DM89JLN Major Decreased metabolism of Conivaptan caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [42]
Brilinta DMBR01X Major Decreased metabolism of Conivaptan caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [42]
Cabozantinib DMIYDT4 Major Decreased metabolism of Conivaptan caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [42]
Sirolimus DMGW1ID Major Decreased metabolism of Conivaptan caused by Sirolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [42]
Saxagliptin DMGXENV Moderate Decreased metabolism of Conivaptan caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [44]
Elagolix DMB2C0E Major Decreased metabolism of Conivaptan caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [125]
Fluticasone DMGCSVF Major Decreased metabolism of Conivaptan caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [126]
Propafenone DMPIBJK Moderate Decreased metabolism of Conivaptan caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [127]
Amiodarone DMUTEX3 Major Decreased metabolism of Conivaptan caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [35]
⏷ Show the Full List of 197 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2203).
2 Emerging diuretics for the treatment of heart failure. Expert Opin Emerg Drugs. 2009 Mar;14(1):195-204.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23.
7 Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79.
8 Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79.
9 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
10 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
11 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
12 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
13 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
15 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
17 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18 Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
19 Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
21 Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009 May 1;419(3):577-84.
22 Vasopressin receptors: structure/function relationships and signal transduction in target cells. J Soc Biol. 2005;199(4):351-9.
23 The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
24 Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95.
25 Post-translational import of protein into the endoplasmic reticulum of a trypanosome: an in vitro system for discovery of anti-trypanosomal chemical entities. Biochem J. 2009 Apr 15;419(2):507-17.
26 Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
27 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030285)
28 Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes. 1999;107(3):157-65.
29 Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44.
30 Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512.
31 Investigational vasopressin receptor modulators in the pipeline. Expert Opin Investig Drugs. 2009 Aug;18(8):1119-31.
32 Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder. J Med Chem. 2020 Feb 27;63(4):1511-1525.
33 Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
34 Clinical pipeline report, company report or official report of Avarx.
35 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
36 Product Information. Cleocin (clindamycin). Pharmacia and Upjohn, Kalamazoo, MI.
37 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
38 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
39 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
40 Multum Information Services, Inc. Expert Review Panel.
41 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
42 Cerner Multum, Inc. "Australian Product Information.".
43 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
44 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
45 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
46 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
47 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
48 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
49 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
50 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
51 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
52 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
53 Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
54 Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3. [PMID: 3421582]
55 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
56 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
57 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
58 Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
59 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
60 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
61 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
62 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
63 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
64 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
65 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
66 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
67 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
68 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
69 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
70 Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
71 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
72 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
73 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
74 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
75 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
76 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
77 Product Information. Sensipar (cinacalcet). Amgen USA, Thousand Oaks, CA.
78 Canadian Pharmacists Association.
79 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
80 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
81 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
82 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
83 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
84 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
85 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
86 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
87 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
88 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
89 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
90 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
91 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
92 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
93 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
94 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
95 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
96 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
97 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
98 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
99 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
100 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
101 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
102 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
103 Product Information. Akynzeo (netupitant-palonosetron). Eisai Inc, Woodcliff Lake, NJ.
104 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
105 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
106 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
107 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
108 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
109 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
110 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
111 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
112 Bird PA, Sturgess AD "Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction." Aust N Z J Med 30 (2000): 635-6. [PMID: 11108077]
113 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
114 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
115 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
116 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
117 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
118 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
119 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
120 Product Information. Fanapt (iloperidone). Vanda Pharmaceuticals Inc, Rockville, MD.
121 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
122 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
123 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
124 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
125 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
126 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]
127 Product Information. Rythmol SR (propafenone). GlaxoSmithKline, Research Triangle Park, NC.